Although IL-22 can be used as a potential prognostic factor in the context of HCC, its dose-dependent differing effects in all stages of hepatocarcinogenesis suggest that, compared with IL-17, IL-22 is at most a minor actor [257]. This evidence concerns the gene IL22 and hepatocellular carcinoma.